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Abstract
Curcumin, the active component of turmeric, has been shown to protect against carcinogenesis and prevent tumor
development. However, little is known about its anti-tumor mechanism in small cell lung cancer (SCLC). In this study, we
found that curcumin can inhibit SCLC cell proliferation, cell cycle, migration, invasion and angiogenesis through suppression
of the STAT3. SCLC cells were treated with curcumin (15 mmol/L) and the results showed that curcumin was effective in
inhibiting STAT3 phosphorylation to downregulate of an array of STAT3 downstream targets ,which contributed to
suppression of cell proliferation, loss of colony formation, depression of cell migration and invasion. Curcumin also
suppressed the expression of proliferative proteins (Survivin, Bcl-XL and Cyclin B1), and invasive proteins (VEGF, MMP-2,
MMP-7 and ICAM-1).Knockdown of STAT3 expression by siRNA was able to induce anti-invasive effects in vitro. In contrast,
activation of STAT3 upstream of interleukin 6 (IL-6) leads to the increased cell proliferation ,cell survival, angiogenesis,
invasion, migration and tumor growth. Our findings illustrate the biologic significance of IL-6/JAK/STAT3 signaling in SCLC
progression and providenovel evidence that the pathway may be a new potential target for therapy of SCLC. It was
concluded that curcumin is a potent agent in the inhibition of STAT3 with favorable pharmacological activity,and curcumin
may have translational potential as an effective cancer therapeutic or preventive agent for SCLC.
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Introduction
Signal transducer and activator of transcription 3 (STAT3)
protein is a member of a family of latent cytoplasmic transcription
factors transmitting signals from the cell surface to the nucleus
activated by cytokines and growth factors. The bond of cell surface
receptors with ligands, such as interleukin-6 (IL-6) or epidermal
growth factor (EGFR), induces tyrosine phosphorylation of
STAT3 protein by Janus kinase and growth factor receptor
tyrosine kinases [1]. The activated dimeric form of phospho-
STAT3 translocates to the nucleus and regulates the expression of
genes containing STAT3-binding sites in their promoters [2]. The
activation of STAT3 protein is rapid and transient in normal cells.
STAT3 regulates fundamental biological processes,including cell
proliferation, survival, and development. Recently, accumulating
evidence indicates that abnormalities in the Janus kinase (JAK)/
signal transducer and activator of transcription (STAT) signaling
pathway are involved in the oncogenesis of several cancers [3].
Activated STAT3 (nuclear pSTAT3) is expressed in about 55%
of NSCLC tumors, as measured by immunohistochemical
analyses[4–6]. STAT3 activation is observed in the majority of
NSCLC cell lines [7,8]. In contrast to NSCLC, strong pSTAT3
expression was demonstrated in 100% (10/10) of SCLC tumor
tissues tested [9]. However, the mechanism by which dysregulated
STAT3 signaling contributes to the progression of human small
cell lung cancer (SCLC) has not been elucidated. SCLC is known
to have a more aggressive biology with rapid growth and early
spread, as well as a common association with paraneoplastic
syndromes [10]. Of all histologic types of lung cancer, SCLC is the
most sensitive to chemotherapy and radiation, but prognosis
remains poor, with an overall median survival following treatment
of 10 months and a 5-year survival of 5% [11]. Elderly lung cancer
patients and those with poor performance status are not treated
with chemotherapy because of the high toxicity of multidrug
regimens. Discovery of novel agents with less severe side effects is
of great necessity. In clinical treatment of cancer patients, many
prescription drugs are derived from natural plant species [12].
Curcumin is derived from turmeric (Curcuma longa) and is
a natural polyphenol. Curcumin has long been used as a food,
coloring agent, and traditional medicine. It is safe and nontoxic
and has demonstrable antitumor, antiinflammatory, apoptotic,
and antioxidant properties [13]. Especially for its anticarcinogenic
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Increasing evidence indicated that curcumin has anticancer effects
against different types of human tumor cells, including of ovarian
cancer cells, colon cancer cells and astroglioma cells [14,15]. This
anticancer effects of curcumin were identified through interfering
with the cell cycle, inducing apoptosis, and inhibiting the invasive
potential of cancers. However, the underlying mechanisms of this
anticancer effects are still under investigation, especially for its
anti-invasive potential in SCLC cancer.We have shown previously
that curcumin inhibits SCLC cell growth and induces SCLC cell
apoptosis [16]. In the present study, we investigated the molecular
mechanisms by which curcumin suppress migration and invasion
in SCLC cells. Our aim was to determine the role of JAK/STAT
signaling in SCLC progression and test the hypothesis that
curcumin could serve as therapeutic targets.
Results
Our goal in this study was to determine whether curcumin
modulates the growth of SCLC cell lines and, if so, to delineate
various mechanisms by which it may mediate its effects. We
examined the effects of curcumin on JAKs activation, STAT3
activation and STAT3-regulated gene products and cell growth in
SCLC (NCI-H446 and NCI-1688 )cells. In a previous study, we
identified a higher p-STAT3 expression level in NCI-H446 cell
lines compared with other human SCLC cell lines. We selected
NCI-H446 cells for this study.
IL-6 induces proliferation of human SCLC cells, and curcumin
or si STAT3 inhibits it. Curcumin or siSTAT3 inhibits the
proliferation of NCI-H446 and NCI-1688 cells. To investigate the
role of STAT3 in the functioning of SCLC cells, STAT3
activation and inhibition were induced with IL-6 and with
siSTAT3 or curcumin, respectively. After transfection with
STAT3 siRNA (siSTAT3) or control siRNA(commercially nega-
tive control), the expression of STAT3 was evaluated using
Western blot and RT-PCR. We found that siSTAT3 significantly
downregulated the protein and mRNA levels of STAT3,
compared with control siSTAT3 (Fig. 1).
To reconfirm previous reports [17,18] that IL-6 induces
proliferation of cancer cells, we serum-starved NCI-H446 and
NCI-1688 cells for 12 h and then cultured them in the absence or
presence of different concentrations of IL-6 for 24 h, 48 h and
72 h. IL-6 induced proliferation of NCI-H446 and NCI-1688 in
a dose-dependent manner. According to the results of our
preliminary experiment, at 25 ng/ml concentrations IL-6 signif-
icantly promoted cell proliferation, compared with 12.5 ng/ml
concentrations, while there were no significant difference between
25 ng/ml and 50 ng/ml concentrations (Fig. 2). The half maximal
inhibitory concentration (IC50) value of curcumin was 15 mMi n
SCLC cells from our previous published paper [16]. Therefore, at
25 ng/ml concentration IL-6 and 15 mM concentration curcumin
were used in the following experiment. SiSTAT3 alone or 15 mM
curcumin had significant effect on cell proliferation, compared
with control cells (Fig. 3). Significant differences were observed
between all time points examined, indicating a linear increase in
proliferation with increasing exposure times to IL-6 (all p,0.05).
Curcumin inhibits SCLC cells migration and invasion. The
inhibitions of NCI-H446 and NCI-1688 cell migration by
curcumin were examined by using wound-healing assays and
transwell migration models and results are shown in Fig. 4 and
Fig. 5A. Curcumin (15 mmol/L) was able to significantly inhibit
NCI-H446 and NCI-1688 SCLC cells migration, and this effect
was consistent across both the wound-healing and transwell
migration models. In addition, the wound-healing assays and
transwell migration model assays indicated that siSTAT3 was able
to inhibit cell migration.IL-6 was able to promote cell migration
and invasion. The Matrigel-based transwell assay indicated that
curcumin or siSTAT3was able to significantly inhibit cell invasion
(Fig. 5B). These results clearly suggest that curcumin exhibits anti-
migration and anti-invasion effects against SCLC cells.
Importance of the IL-6/JAK/STAT3 pathway in anchorage-
independent growth. The anchorage-independent growth of
SCLC cells was determined in a soft agar assay [19]. NCI-H446
cells were able to build large aggregates in the soft agar during the
15 days observation period. In contrast, there was no proliferation
in the presence of siSTAT3 or curcumin, which suggests
a contribution for this pathway in this process. There was
a complete promote by the IL-6, suggesting importance of this
pathway in anchorage-independent growth (Fig. 6). In the first
week, The cells looked quite similar under the microscope except
for the fact that the inhibited ones did not proliferate. However,
after 7–14 days cells inhibited with curcumin began to change
their morphology.
Curcumin causes G2/M Phase cell cycle arrest in NCI-H446
cells. To determine whether curcumin inhibits the cell cycle
progression of NCI-H446 cells, cells were grown to 70%
confluence and the cell cycle distribution was analyzed by flow
cytometry after a 12- and 24-h exposure to curcumin (15 mM). It
was observed that the percentage of cells in G2/M phase with
curcumin treatment was 52.2% after 12 h of incubation and
decreased to 21.2% after 24 h. The percentage of cells in sub-G0/
G1 phase was 3.5% and 37.1% after 12 and 24 h of incubation,
respectively. In control cells the percentage of cells in G2/M and
Sub-G0/G1 phase was 21.7% and 1.1% respectively(Table 1).
To determine the possible mechanism by which curcumin
influences the G2/M phase distribution in NCI-H446 cells, the
expression of Cyclin B1 was assessed using RT-PCR and Western
blot. Compared with control cells, the curcumin significantly
downregulated the mRNA and protein levels of Cyclin B1, which
is related to G2/M phase progression (Fig. 7). The siSTAT3 had
significant effect on the levels of Cyclin B1 expression. Compared
with control cells, the IL-6 significantly upregulated the protein
and mRNA levels of Cyclin B1. Taken together, the results above
manifest that curcumin inhibits proliferation of SCLC cancer cell
and blocks it in G2 phase through suppressing the expression of
Cyclin B1.
Curcumin inhibits IL-6 inducible STAT3 phosphorylation in
a dose and time dependent manner. To examine if curcumin that
was designed to selectively target STAT3 would show similar
inhibitory effect on STAT3 phosphorylation, NCI-H446 cells
were cultured in serum free medium overnight and then were pre-
treated with different concentrations of curcumin for 1 hours or
15 mM curcumin for different time. After the treatment, total
protein was extracted and phosphorylated STAT3 and total
STAT3 were analyzed by western blot. As shown in Figure 8,
curcumin inhibited STAT3 phosphorylation on tyrosine 705 in
a dose dependent and time manner. Total STAT3 was not
affected by the treatment of curcumin.
Given that IL-6-induced signals are mediated through STAT3
phosphorylation, it is logical to then investigate the effect of IL-6
and curcumin on STAT3 phosphorylation in SCLC cells.
Although SCLC cells express high levels of Tyr705p-STAT3
(Fig. 8A and B). Figure 8C shows that IL-6-induced STAT3
phosphorylation in SCLC cells was reduced by curcumin
treatment. Exposure of cells to curcumin for 1 h markedly
suppressed IL-6-induced STAT3 phosphorylation in NCI-H446
cells.
Curcumin Blocks SCLC Cells Migration and Invasion
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Phosphorylation of STATs depends on the activation of JAKs.
Members of the JAK family of protein tyrosine kinases phosphor-
ylate phosphorylate and activate cytoplasmic STAT proteins.
JAK-2 is a recognized activator of STAT3 [20]. We investigated
whether the inhibitory effects of curcumin on the activation of
STAT were due to the suppression of JAK expression in SCLC
cells.Curcumin inhibited p-JAK-1, p-JAK-2 and p-JAK-3 expres-
sion in NCI-H446 cells (Fig. 9). Expression of total JAK-1, JAK-2
and JAK-3 was not altered by curcumin treatment.
Curcumin-inhibited levels of MMP-2, MMP-7, VEGF, Survi-
vin, Bcl-XL and ICAM-1 in SCLC cells. Levels of migration,
invasion and angiogenesis associated proteins in NCI-H446 cells
after treatment with curcumin were determined and quantitated
by Western blotting. Results were shown in Figure10 indicate that
the levels of MMP-2, MMP-7, VEGF and Survivin (Fig 10A).
BCL-XL and ICAM-1 (Fig. 10B) were lower than the correspond-
ing control group. These proteins play an important role of cell
migration, invasion and angiogenesis. These effects may have led
to the inhibition of migration, invasion and angiogenesis from
NCI-H446 cells after exposure to curcumin at 15 mM.
Discussion
SCLC represents a highly malignant and particularly aggressive
form of cancer, with early and widespread metastasesand a poor
prognosis. To date, there is no data delineating the effects of
curcumin on proteins regulating STAT3 signaling in SCLC.
Several studies employing genetic and pharmacological ap-
proaches to modulate constitutive signal transducer and activator
of transcription 3 (STAT3) activity have substantiated the critical
role of aberrant STAT3 activity in malignant transformation and
tumor progression, and hence endorse STAT3 as a novel cancer
drug target [21].
Figure 1. Efficiency of STAT3 siRNA in SCLC cells. Cells were transfected with control siRNA or STAT3 siRNA(si STAT3). After transfection, the
expression of STAT3 protein (A) and mRNA (B) was evaluated using Western blot and RT-PCR and compared to untransfected NCI-H446 and NCI-
H1688 cells. The columns ‘‘NCI-H446 and NCI-H1688 cells’’ correspond to the untreated cells respectively. The columns ‘‘siSTAT3’’ correspond to the
transfected with STAT3 siRNA.The columns ‘‘control’’ correspond to the transfected with control siRNA. Each bar represents the mean 6 SD of three
independent experiments. *p,0.05, compared with control cells.
doi:10.1371/journal.pone.0037960.g001
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PLoS ONE | www.plosone.org 3 May 2012 | Volume 7 | Issue 5 | e37960Figure 2. Effect of IL-6 at various concentrations on proliferation of SCLC cells. Cells were treated with IL-6(12.5, 25 or 50 ng/ml) for 24, 48,
or 72 h, and cell vitality was estimated using the Brdu assay. Each bar represents the mean 6 SD of three independent experiments. p,0.05 or
** p,0.01, compared with cells untreated with IL-6.
doi:10.1371/journal.pone.0037960.g002
Figure 3. Effect of siSTAT3 or curcumin on proliferation of NCI-H446 cells. Cells were treated with curcumin (15 mM)for 24, 48, or 72 h, and
cell vitality was estimated using the Brdu assay. Each bar represents the mean 6 SD of three independent experiments. * p,0.05 or ** p,0.01,
compared with the untreated cells.
#p,0.05 or
##p,0.01, compared with the transfected with control siRNA cells.
doi:10.1371/journal.pone.0037960.g003
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PLoS ONE | www.plosone.org 4 May 2012 | Volume 7 | Issue 5 | e37960Figure 4. The wound-healing assay for evaluating the inhibitory effects of curcumin on SCLC cell migration. Confluent monolayers of
cells were scarred, and repair was monitored microscopically after 24 h of treatment with curcumin 15 mM or IL-6 25 ng/ml. The representative
photographs showed the same area at time zero and after 24 h of incubation with or without curcumin. Each bar represents the mean 6 SD of three
independent experiments. * p,0.05 or ** p,0.01, compared with control cells.
doi:10.1371/journal.pone.0037960.g004
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PLoS ONE | www.plosone.org 5 May 2012 | Volume 7 | Issue 5 | e37960Figure 5. A, the Transwell migration assay showed the inhibitory effects of curcumin on NCI-H446cell migration. After 8 h of
incubation with or without the indicated concentration of curcumin, cells that migrate to the lower chamber were fixed, stained, and counted using
light microscopy or flurescent microscopy–based high content screening system, as describe in Materials and Methods. Random fields were scanned
(four fields per filter of the well) for the presence of cells on the lower side of the membrane. Each bar represents the mean 6 SD of three
independent experiments. * p,0.05, compared with control cells.
#p,0.05 compared with cells treated with IL-6 (25 ng/ml). B, the effect of
curcumin treatment on cell invasion was determined using the Matrigel Invasion Assay System. NCI-H446 cells in serum-free medium with or without
curcumin were seeded into the upper chamber of the system. The bottom well was filled with complete medium. After 16 h of incubation, the cells
that had invaded through the Matrigel membrane were stained with 20% Giemsa solution and counted under a light microscope (magnification,
6200). The experiments were performed thrice in triplicate. Each bar represents the mean 6 SD of three independent experiments. * p,0.05,
compared with control cells.
#p,0.05 compared with cells treated with IL-6 (25 ng/ml).
doi:10.1371/journal.pone.0037960.g005
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PLoS ONE | www.plosone.org 6 May 2012 | Volume 7 | Issue 5 | e37960Curcumin (diferuloylmethane), an anti-inflammatory agent used
in traditional medicine, has been shown to suppress cellular
transformation, proliferation, invasion, angiogenesis, and metas-
tasis through a mechanism not fully understood. Because several
genes that mediate these processes are regulated by signal
transducer and activator of transcription, we have postulated that
curcumin mediates its activity by modulating STAT3 activation.
In this study, we investigated the mechanism by which curcumin
manifests its effect on STAT3 and STAT3-regulated downstream
gene expression. We showed that curcumin down-regulated the
expression of STAT3-regulated gene products involved in cellular
cycle (Cyclin B1), survival (Bcl-XL, Survivin), angiogenesis
(vascular endothelial growth factor) and metastasis (matrix
metalloproteinase-2, matrix metalloproteinase-7 and intercellular
adhesion molecule-1). Traditionally, the cell cycle is segregated
into four phases: DNA replication occurs during S phase, and
chromosome segregation occurs during M phase. The S and M
phases are separated by the so-called gap phases, G1 (before DNA
replication) and G2 (before mitosis). Our study demonstrated that
curcumin inhibited the NCI-H446 cells proliferation by inducing
G2/M cell cycle arrest leading to apoptotic cell death. No
significant differences were observed regarding the distribution of
cells in the G0/G1 and S phases. In this study, both protein and
mRNA levels of Cyclin B1 were significantly downregulated when
cells were treated with curcumin for 24 h. Cyclin B1, which is
overexpressed in a variety of tumors, is regulated by STAT3 and is
required for cells to advance from the G2 phase to the M phase of
the cell cycle [22,23]. This finding demonstrates for the first time
that curcumin has an arrest effect on cell cycle progression
involving the G2/M phase in SCLC cells. It also may explain the
antiproliferative effects of curcumin. Our laboratory has shown
previously that curcumin can induce SCLC cells apoptosis. In
addition to the constitutive activation of STAT3, we were able to
demonstrate that stimulation of SCLC cells with IL-6 increased
the STAT3 phosphorylation in SCLC cells.Our results strengthen
the potential of curcumin as a multitarget drug in anticancer
therapy.
Our finding that curcumin inhibited the SCLC cell invasion
through down-regulation of the expression of STAT3 regulated
gene products involved in cell invasion (e.g., MMP-2 and MMP-7).
The down-regulation of VEGF as shown here could explain the
antimetastatic activities of curcumin [24]. ICAM-1 has been
implicated in carcinogenic processes, and its overexpression by
malignant cells has been shown to enhance cellular invasion,
induce angiogenesis, regulate antiapoptotic cellular defenses, and
augment immunologic resistance through production of prosta-
glandin E2 [25]. MMP-2 and MMP-9 plays a crucial role in tumor
invasion and angiogenesis by mediating degradation of the
extracellular matrix, and inhibition of MMP activity has been
shown to suppress lung cancer metastasis [26].
To investigate the mechanism of curcumin-induced STAT3
inhibitory effects in SCLC cells, we analyzed proteins upstream of
STAT3. The roles of JAK have been implicated in STAT3
activation. As shown in Figure 8C and 9B, phosphorylation of
JAK-1, JAK-2 and JAK-3 were suppressed by treatment with
curcumin in SCLC cells. It is likely that the inhibition of Tyr705
STAT3 is due to the inhibition of JAK because the inhibition of
JAK phosphorylation occurred within 30 min after the treatment,
whereas STAT3 phosphorylation was inhibited within 1 hour after
the treatment. This suggests that curcumin could manifest its effect
on STAT3 activation through the inhibition of JAKs. In a previous
study, our laboratory found that curcumin selectively inhibits
STAT3 tyrosine phosphorylation but does not affect serine
phosphorylation of STAT3 in SCLC cells. These results are in
accordance with studies by Saydmohammed et al [27]. They
found that curcumin failed to inhibit the phosphorylation of
STAT3 at Ser727 in endometrial and ovarian cancer cells. Upon
IL-6 stimulation, STAT3 is quickly phosphorylated on Tyr705
Figure 6. Anchorage-independent growth in soft-agar. Colony formation of the NCI-H446 cells and the indicated stable sublines in soft agar.
Cells were observed using an inverted microscope (6400) in soft agar for 15 days. The columns ‘‘control’’ correspond to the transfected with control
siRNA.
doi:10.1371/journal.pone.0037960.g006
Table 1. Curcumin causes G2/M arrest of SCLC cells.
Group Sub-G0/G1 phase G0/G1 phase S phase G2/M phase
Mean 6 SD(%) Mean 6 SD(%) Mean 6 SD(%) Mean 6 SD(%)
Control 1.162.13 49.265.45 27.666.81 21.765.49
Curcumin 12 h 3.561.36 18.768.36 24.267.12 52.264.75*
Curcumin 24 h 37.164.29* 28.366.47 13.266.93 21.262.48
Curcumin causes G2/M arrest of NCI-H446 cells. NCI-H446 cells were treated with curcumin (15 mM) for 24 h, and cell cycle distribution was estimated using flow
cytometry. Data were present as mean 6 SD of three independent experiments. *p,0.05, compared with control cells.
doi:10.1371/journal.pone.0037960.t001
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PLoS ONE | www.plosone.org 7 May 2012 | Volume 7 | Issue 5 | e37960and translocated to the nucleus. Our results further indicate that
IL-6 mediated STAT3 Tyr705 phosphorylation is mainly a nuclear
event.
In many tumors and cancer cells, constitutive activation of
STAT3 is IL-6 dependent, through either autocrine or paracrine
signaling, which seems to be widely expressed in cancer cell lines
[28]. In some cases, the activation of the STAT3 pathway is
correlated with brisk intratumoral inflammatory cells infiltration,
which means that STAT3 activation may be via paracrine
mechanisms [29]. As to this case, inhibition of STAT3 caused
decreased production of IL-6.The activation of STAT3 pathway
has been studied in patients’ tumor tissue samples. The levels of p-
STAT3 expression correlated with the survival rate and severity of
chordoma [30]. Recent studies have also linked the activation of
STAT3 pathway to high histologic grade and advanced stage in
several cancers [31]. These results suggested that STAT3 may not
only serve as a predictive marker of drug resistance, but also as
a prognosis marker of tumors [32].
In summary, prior to this report, there was no information on
the status of JAK/STAT3 signaling proteins in SCLC cells and
their regulation by curcumin. This study is the first to have
examined in detail curcumin anti-cancer mechanistic role of JAK/
STAT3 signaling in SCLC tumorigenesis and progression. The
significance of this study is that we have identified a perturbance in
a plethora of JAK/STAT signaling proteins in cancer cells. Thus,
STAT3 plays a significant role in SCLC oncogenesis and could be
a potential therapeutic target for SCLC treatment.
Figure 7. Effect of IL-6, curcumin or siSTAT3 on the expression of CyclinB1. NCI-H446 cells were treated with IL-6 (25 ng/ml)or curcumin
(15 mM) for 24 h. The expression levels of these components were estimated using RT-PCR(A) and Western blot(B). Each bar represents the mean 6
SD of three independent experiments. * p,0.05 compared with control cells.
#p,0.05 compared with cells treated with IL-6 (25 ng/ml).
doi:10.1371/journal.pone.0037960.g007
Figure 8. Curcumin attenuates Tyr705p-STAT-3 in SCLC cells. A: To study the dose-dependent effect the NCI-H446cells were treated with
different concentrations of curcumin for 1 h. B: To study the time-dependent effect, cells were treated with curcumin (15 mM ) for 30, 60 and 120 min.
C: To study the effect of curcumin on IL-6-induced p-STAT-3, cells were cultured asdescribed above except that cells were pretreated with IL-6 (25 ng/
ml) for 1 h prior to treatment with curcumin (15 mM) for 1 h. Cells were removed at indicated times and lysed to prepare the whole-cell extract. Cells
were harvested and 20 mg of protein from the whole-cell extract was loaded in each lane. GAPDH was used as a loading control. Each bar represents
the mean 6 SD of three independent experiments. *p,0.05 compared with control cells.
#p,0.05 compared with cells treated with IL-6 (25 ng/ml).
doi:10.1371/journal.pone.0037960.g008
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PLoS ONE | www.plosone.org 8 May 2012 | Volume 7 | Issue 5 | e37960Figure 9. Effect of curcumin treatment on protein expression of P-JAK1, P-JAK2 and P-JAK3. NCI-H446 cells were treated with dfferent
concentration of curcumin for 30 min.These proteins were assayed by Western blotting. Equal amounts of total cellular protein (20 mg) were resolved
by 10%–15% SDS-PAGE. GAPDH was used as a loading control. Each bar represents the mean 6 SD of three independent experiments. * p,0.05
compared with control cells.
Figure 10. A and B. Effect of curcumin treatment on protein expression of MMP-2, MMP-7, VEGF, Survivin, Bcl-XL and ICAM-1. NCI-
H446 cells were treated with 15 mM curcumin for 24 h. These proteins were assayed by Western blotting. Equal amounts of total cellular protein
(20 mg) were resolved by 10%–15% SDS-PAGE. GAPDH was used as a loading control. Each bar represents the mean 6 SD of three independent
experiments. * p,0.05 compared with control cells.
#p,0.05 compared with cells treated with IL-6(25 ng/ml).
doi:10.1371/journal.pone.0037960.g010
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Chemicals and Antibodies
Curcumin (1,7-bis[4-hy-droxy-3-methoxyphenyl]-1,6-hepta-
diene-3,5-dione) was purchased from Sigma-Aldrich(St. Louis,
MO), dissolved in DMSO at a stock concentration of 10 mM, and
diluted to the indicated concentration with RPMI 1640 medium.
The antibodies for Survivin, Bcl-XL, Cyclin B1, P-JAK1, JAK1, P-
JAK2, JAK2, P-JAK3, JAK3, Tyr
705-pSTAT3 and STAT3 were
purchased from Cell Signaling Technology (Beverly,MA). The
antibodies for VEGF, ICAM-1, MMP-2, MMP-7, and GAPDH
were purchased from Santa Cruz Biotechnology (Santa Cruz, CA,
USA). siSTAT3 and Lipofectamine 2000 were purchased from
Invitrogen (Carlsbad, CA, USA). Other chemicals were purchased
from Sigma-Aldrich.
Cell Culture
NCI-H446 and NCI-1688 (human SCLC) cell lines from our
previous published paper [15] were cultured in RPMI-1640
supplemented with 10% HyClone fetal bovine serum (FBS)
(ThermoFisher Scientific, Fremont, CA, USA) in an atmosphere
of 5% CO2 at 37uC.Cells were grown in 75 cm
2 culture flasks and
harvested in a solution of trypsin-EDTA at the logarithmic growth
phase.
Plasmids and siRNAs
The plasmids pcDNA6.2-STAT3 and control vectors(a domi-
nant-negative mutant of STAT3) were described previously [33].
siRNA sequences targeting STAT3a were as follows: F,59-
TGCTGAATGCAGGCAATCTGTTGCCGGTTTTGG
CCACTGACTGACCGGCAACATTGCCTGCATT-39 and
R,59-CCTGAATGCAGG CAATGTTGCCGGTCAGT-
CAGTGGCCAAAACCGGCAACAGATTGCCTGCATTC-39.
Negative control: F,59-TGCTGAAATGTACTGCGCGTGGA-
GACGTTTTG GCCACTGACTGACGTCTCCACGCAGTA-
CATTT-39 and R, 59-CCTGAAATGTA CTGCGTGGA-
GACGTCAGTCAGTGGCCAAAACGTCTCCACGCGCAG-
TACATTC-3.
Transient and Stable Transfection
Transfection of plasmids and siRNAs into small cell lung cancer
cells was done by using Lipofectamine 2000 (Invitrogen). For
transient transfection, cells were transfected with siRNA or
plasmids at different doses as indicated for 48 hours before
functional assays were carried out. Stably transfeted cell lines were
isolated from SCLC cells transfected with pcDNA6.2-STAT3
plasmid via selection with Blasticidin (Invitrogen, 5 mg/ml).
Cell Proliferation Assay
Proliferation of SCLC cells was determined by analysing 59-
Bromo-29-deoxyuridine (Brdu) incorporation into newly synthe-
sised DNA using a cell proliferation enzyme linked immunosor-
bent assay (Cell proliferation ELISA (Brdu), Roche, Mannhein,
Germany). For the Brdu incorporation assay, cells were counted
and seeded into 96-well culture plates (2610
3 cells/well). Brdu
(10 ml/well) was added SCLC cells were fixed and stained after
4 h according to the manufacturer’s instructions. Colorimetric
analysis was performed with an ELISA plate reader (DTX880;
Beckman, Miami, FL) at 450 nm.
Cell Cycle Analysis by Flow Cytometry
After treatment with curcumin for 24 h, SCLC cells were
harvested and washed twice with cold phosphate-buffered saline
(PBS) and fixed in 75% ethanol for 2 h at 4uC. The fixed cells
were washed twice with 500 ml of cold PBS. Cells then were
stained with 500 ml of propidium iodide (PI) staining solution
(50 mg/ml PI, 0.1%Triton X-100, 200 mg/ml DNase-free RNase
in PBS) for 30 min at room temperature in the dark. Ten
thousand events per sample were acquired using a FACS-scan flow
cytometer (Becton-Dickinson, San Jose, CA, USA), and the
percentage of cells in G0/G1,S ,G 2/M and Sub-G2/M phases
of the cell cycle were determined using CELLQuest software
(Becton-Dickinson).
The Wound-Healing Assay
The SCLC cells were cultured in 24-well plates and grown in
medium containing 10% FBS to nearly confluent cell monolayer,
then carefully scratched using a plastic pipette tip to draw a linear
‘‘wound’’ in the cell monolayer of each well. The monolayer was
washed twice with PBS to remove debris or the detached cells
from the monolayer, and then curcumin was added by 15 mM; IL-
6 was added by 25 ng/ml; the control well was added with 0.1%
of DMSO as the solvent control. The cultures were incubated at
37uC and photographedimmediately and monitored by time lapse
in the Carl Zeiss Axiovert Bio-station system. Under the
microscope, the number of cells that migrated into the cell-free
zone, base on the line of the linear ‘‘wound’’ was evaluated. The
experiments were performed thrice in triplicate and were counted
double blind by at least two investigators.To investigate cell
motility, monolayers of SCLC cells were prepared and wounded
as described above.The wounded monolayers were incubated at
37uC in RPMI-1640 containing 10% FBS with mitomycin C
(10 mg/ml, Sigma) to block mitosis.
The Transwell Migration Assay
The cancer cell transwell migration assay was performed
according to previous study and partially modified [34]. Briefly,
Transwell membrane (Corning Costar Corporation) was used.
The SCLC cells were trypsinized, washed, and kept suspended in
medium without FBS. To the lower wells of the chambers,
migration-inducing medium (with 10% FBS) were added. Upper
wells were filled with serum-free medium with cells (20,000 cells
per well), in some cases, also containing 15 mmol/L of curcumin
or 25 ng/ml of IL-6. Then, the chamber was placed into
a humidified incubator. After 8 h, assays were stopped by removal
of the medium from the upper wells and careful removal of the
filters. Filters were fixed with methanol by brief submersion and
were subsequently wiped on the cells on the upper side using the
Q-tip. Filters were stained with 20% Giemsa solution for the light
microscope or 4–6-diamidino-2-phenylindole for the fluorescent
microscopy–based high content screening system (Cellomics).
Evaluation of completed transmigration was performed under
the microscope, and random fields were scanned (four fields per
filter) for the presence of cells at the lower membrane side only.
Invasion Assay
The cancer cell invasive ability with or without indicated
treatment was examined by membrane transwell culture system.
Briefly, Transwell membrane (Corning Costar Corporation)
coated with Matrigel (2.5 mg/ml; BD Biosciences Discovery
Labware) was used for invasion assay. Cells were trypsinized,
centrifuged, and resuspended at 10
6 cells/ml in RPMI 1640. Cells
were seeded onto the upper wells of precoated transwells, 2610
4
cells per well. Lower wells of the transwells contained the same
medium with 10% FBS. After 16 h of incubation, the cells on the
upper well and the membranes coated with Matrigel were
swabbed with a Q-tip, fixed with methanol, and stained with
Curcumin Blocks SCLC Cells Migration and Invasion
PLoS ONE | www.plosone.org 10 May 2012 | Volume 7 | Issue 5 | e3796020% Giemsa solution. The cells that penetrated through filter were
counted at a magnification of6200 in 15 randomly selected fields,
and the mean number of cells per field was recorded. The
experiments were performed thrice in triplicate.
Colony Formation in Soft-Agar Assay
Cells (5610
3 cells per well) were mixed with 0.3% agar solution
in RPMI 1640 containing 10% FBS, and the solution was poured
on top of a 0.60% agar layer containing RPMI 1640 and 10%
FBS in 12-well tissue culture plates. After 15 days in culture,
colonies were then stained with 0.005% crystal violet and
examined using Bio-Rad Quantity One software (Hercules, CA).
Reverse Transcription–Polymerase Chain Reaction Assay
Total RNA was isolated from cells using TRIzol (Invitrogen)
according to the manufacturer’s instructions. To determine the
efficiencies of siSTAT3 and control siRNA, semi-quantitative RT-
PCR was performed on a G-STORM thermal cycler (GRI Ltd,
Byfleet, UK) using the TaKaRa RNA PCR Kit (AMV) Ver.3.0
(TaKaRa, Dalian, China). The primers were designed and
synthesized by Shenggong Biotech Company according to the
serial number from GenBank as shown in Table 2. The reaction
was started at 94uC for 2 min, amplified for 35 cycles of 30 s at
94uC, 60 s at 55uC (for STAT3), 45 s at 57uC (for CyclinB1), or
30 s at 72uC and ended with a 5 min extension at 72uC. GAPDH
mRNA was used as an internal control and coamplified with
STAT3 or Cyclin B1 mRNA. The products were visualized by
electrophoresis on a 1.5% agarose gel, and the density of each
band was analyzed using the Gel Image Analysis System (Tanon
2500R).
Western Blot
Total protein from cells was extracted in lysis buffer (Pierce) and
quantified using the BCA method. A total of 20 mg of protein was
separated using 10%–15% SDS-PAGE and then electrophoreti-
cally transferred to a PVDF membrane (Millipore).The membrane
was blocked with 5% nonfat milk in TBST solution and incubated
at 4uC overnight with primary antibody in blocking solution. After
washing three times with TBST, the membrane was incubated at
room temperature for 1 h with horseradish peroxidase–conjugated
secondary antibody diluted in TBST. Protein bands were
visualized using enhanced chemiluminescence (Pierce) and
detected using. BioImaging Systems (UVP). The relative protein
levels were calculated based on GAPDH protein as a loading
control.
Statistical Analysis
SPSS 13.0 software was used for statistical analysis. Data were
summarized as mean 6 SD. Student’s t-tests were used to
determine the significant differences between groups. Results were
considered to be significant for p-values of ,0.05.
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